386: Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate
cancer: new therapies, novel combination strategies and implications for
immunotherapy. Oncogene. 2014 Oct 23;33(43):5053-5064. doi: 10.1038/onc.2013.497.
Epub 2013 Nov 25. Review. PubMed PMID: 24276248.


387: Drake CG. Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,'
'Tough Neighborhoods,' or 'Evil Humors'? Oncology (Williston Park). 2014 Nov
15;28(11). pii: 202395. Review. PubMed PMID: 25403629.


388: Drake CG. The potential role of antigen spread in immunotherapy for prostate
cancer. Clin Adv Hematol Oncol. 2014 May;12(5):332-4. PubMed PMID: 25003491.


389: Drake CG. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in
castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Sep
19;104(18):1422; author reply 1422-3. Epub 2012 Aug 21. PubMed PMID: 22911668.


390: Drake CG, Antonarakis ES. Current status of immunological approaches for the
treatment of prostate cancer. Curr Opin Urol. 2012 May;22(3):197-202. doi:
10.1097/MOU.0b013e3283519ad5. Review. PubMed PMID: 22328018; PubMed Central
PMCID: PMC3444809.


391: Drake CG. Update on prostate cancer vaccines. Cancer J. 2011
Sep-Oct;17(5):294-9. doi: 10.1097/PPO.0b013e3182325e78. Review. PubMed PMID:
21952278; PubMed Central PMCID: PMC3420819.


392: Drake CG, Antonarakis ES. Update: immunological strategies for prostate
cancer. Curr Urol Rep. 2010 May;11(3):202-7. doi: 10.1007/s11934-010-0106-8.
Review. PubMed PMID: 20425628; PubMed Central PMCID: PMC4020436.


393: Drake CG. Immunotherapy for prostate cancer: an emerging treatment modality.
Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents. doi:
10.1016/j.ucl.2009.11.001. Review. PubMed PMID: 20152525.


394: Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev
Immunol. 2010 Aug;10(8):580-93. doi: 10.1038/nri2817. Review. PubMed PMID:
20651745; PubMed Central PMCID: PMC3082366.


395: Drake CG. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol. 
2009 Sep 1;27(25):4035-7. doi: 10.1200/JCO.2009.22.2299. Epub 2009 Jul 27. PubMed
PMID: 19635998.


396: Drake CG. Immunotherapy for metastatic prostate cancer. Urol Oncol. 2008
Jul-Aug;26(4):438-44. doi: 10.1016/j.urolonc.2007.03.029. Epub 2007 Dec 21.
Review. PubMed PMID: 18593624.


397: Drake CG. Basic overview of current immunotherapy approaches in urologic
malignancy. Urol Oncol. 2006 Sep-Oct;24(5):413-8. PubMed PMID: 16962493.


398: Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL,
Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, Pardoll DM, Adler 
AJ. Androgen ablation mitigates tolerance to a prostate/prostate
cancer-restricted antigen. Cancer Cell. 2005 Mar;7(3):239-49. PubMed PMID:
15766662; PubMed Central PMCID: PMC2846360.